Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Urovant Sciences Stock Is Skyrocketing Today

By Keith Speights - Nov 13, 2020 at 12:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's biggest shareholder plans to acquire all of Urovant.

What happened

Shares of Urovant Sciences ( UROV ) were skyrocketing 93.8% higher as of 11:40 a.m. EST on Friday. The huge gain came after the company announced that it has entered into a definitive agreement to be acquired by Sumitovant Biopharma for $584 million. 

So what

Sumitovant Biopharma was already Urovant's largest shareholder, owning around 72% of the company. Urovant CEO James Robinson said his company has "been partnering closely with [Sumitovant] on plans to efficiently launch vibegron and achieve scale as quickly as possible." Vibegron is Urovant's lead pipeline candidate that's in late-stage testing for potentially treating overactive bladder.

Woman drawing big fish about to eat smaller fish

Image source: Getty Images.

The transaction price represents a 96% premium over Urovant's closing share price on Thursday. It's also a 92% premium over the 30-day volume-weighted average price for the biotech stock.

Pierre Legault, the lead independent member of Urovant Sciences' board of directors, said "Sumitovant's offer represents exceptional value for shareholders." Robinson added, "We believe that this investment represents a vote of confidence in Urovant's future success and will put us in an even stronger position to bring vibegron to market as a new treatment option for patients with overactive bladder and to continue advancing our promising development pipeline."

Now what

Urovant's shareholders must first approve the acquisition. The deal is expected to close in the first quarter of 2021. Urovant hopes to win U.S. regulatory approval for vibegron even sooner. The FDA is scheduled to make its decision on approval for the drug by Dec. 26, 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Urovant Sciences Ltd. Stock Quote
Urovant Sciences Ltd.
UROV

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.